SHP-141C in Plaque Type Psoriasis

• Status: Completed
• Trial end date: 2012-11-01

Summary

The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.

• Phase: Phase 1

Details

• Lead Sponsor: TetraLogic Pharmaceuticals
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene; Calcitriol